指南与共识头颈外科

头颈部鳞状细胞癌治疗后随访指南依从性的价值

Value of Adherence to Posttreatment Follow-Up Guidelines for Head and Neck Squamous Cell Carcinoma.
指南 / 共识 · Laryngoscope · 2023-07-26

本研究在学术医疗中心回顾452例头颈部鳞状细胞癌患者,按美国国家综合癌症网络(NCCN)随访指南依从性分组,分析依从性与复发及生存的关联。结果显示治疗后第一年依从率为23.5%,5年持续依从率为15.9%;第一年依从与5年总生存(HR 0.634;95%CI 0.443-0.906;p=0.0124)和疾病特异性生存(HR 0.556;95%CI 0.312-0.992;p=0.0470)显著相关,但5年持续依从未显示显著关联。

要点

  • 治疗后第一年NCCN随访指南依从率为23.5%,5年持续依从率为15.9%。
  • 第一年依从与5年总生存(HR 0.634)和疾病特异性生存(HR 0.556)显著相关。
  • 5年持续依从与生存未显示显著关联。

核心结论

  • 治疗后第一年依从NCCN随访指南与更好的5年总生存和疾病特异性生存机会相关,但5年持续依从者中未观察到这一显著关联。

研究设计与样本

  • 在学术医疗中心的社会经济弱势城市环境中诊断的452例头颈部鳞状细胞癌患者,按NCCN随访指南依从性分类,进行生存分析。

主要发现

  • 23.5%的患者在治疗后第一年依从NCCN随访指南,15.9%在5年内持续依从。
  • 第一年依从与5年总生存显著相关(HR 0.634;95%CI 0.443-0.906;p=0.0124),与疾病特异性生存显著相关(HR 0.556;95%CI 0.312-0.992;p=0.0470)。
  • 5年持续依从未显示与生存的显著关联。
  • 队列中21.7%的患者出现复发,依从与早期复发(AJCC I/II期)无关;在该亚组中,第一年依从与疾病特异性生存改善相关,但与总生存无关,5年持续依从与生存无关。

关键数值与推荐

  • 第一年依从与5年总生存:HR 0.634(95%CI 0.443-0.906;p=0.0124)。
  • 第一年依从与5年疾病特异性生存:HR 0.556(95%CI 0.312-0.992;p=0.0470)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The utility of intensive posttreatment surveillance of head and neck squamous cell carcinoma (HNSCC) has been debated. The objective is to investigate adherence to the National Comprehensive Cancer Network (NCCN) posttreatment follow-up guidelines and assess the association with recurrence and survival. METHODS: A total of 452 patients diagnosed with HNSCC at an academic medical center in a socioeconomically disadvantaged, urban setting were categorized by adherence to NCCN follow-up guidelines. Survival analyses were conducted to study the association between adherence and the 5-year overall survival and disease-specific survival in the entire cohort and subset of patients with documented recurrence. RESULTS: We found that 23.5% of patients were adherent to NCCN follow-up guidelines in the first year after treatment, and 15.9% were adherent over 5 years. Adherence in the first year was significantly associated with 5-year overall survival (HR 0.634; 95% CI 0.443-0.906; p = 0.0124) and disease-specific survival (HR 0.556; 95% CI 0.312-0.992; p = 0.0470), but consistent adherence over 5 years did not show a significant association. Among the 21.7% of the cohort with recurrence, adherence was not associated with early-stage recurrence (AJCC stage I/II). In this subset, first year adherence was associated with improved disease-specific but not overall survival, and adherence over 5 years was not associated with survival. CONCLUSION: Adherence to NCCN follow-up guidelines in the first year after treatment was associated with a better chance of 5-year overall and disease-specific survival, but this significant association was not observed among those who demonstrated consistent adherence over 5 years. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:708-716, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Stone A, Liu J, Lin J, et al. Value of Adherence to Posttreatment Follow-Up Guidelines for Head and Neck Squamous Cell Carcinoma. Laryngoscope. 2023. PMID: 37493178. doi:10.1002/lary.30909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。